Results 321 to 330 of about 645,099 (360)
Some of the next articles are maybe not open access.
Hepatitis B virus immunopathology
Springer Seminars in Immunopathology, 1995Approximately 5% of the world population is infected by the hepatitis B virus (HBV) which causes a necroinflammatory liver disease of variable duration and severity. Chronically infected patients with active liver disease carry a high risk of developing cirrhosis and hepatocellular carcinoma.
Chisari, F. V, FERRARI, Carlo
openaire +2 more sources
Transmission of Hepatitis B Virus
Annals of Internal Medicine, 1982Excerpt To the editor: The article by Reiner and associates in the February issue (1) presents evidence to support de facto parenteral transmission as a source of hepatitis B virus (HBV) infections...
R M, Scott, W H, Bancroft, R, Snitbhan
openaire +2 more sources
Myocarditis and Hepatitis B Virus
Angiology, 1985Two patients with hepatitis B virus infection and myocarditis are reported. The implicated pathogenesis was an immune complex mechanism in one pa tient. Both patients presented with heart failure and arrythmia which were con trolled with conventional medical therapy.
R K, Mahapatra, G H, Ellis
openaire +2 more sources
Hepatitis B Virus Immunopathogenesis
Annual Review of Immunology, 1995Approximately 5% of the world population is infected by the hepatitis B virus (HBV) that causes a necroinflammatory liver disease of variable duration and severity. Chronically infected patients with active liver disease carry a high risk of developing cirrhosis and hepatocellular carcinoma.
Chisari, F. V, FERRARI, Carlo
openaire +3 more sources
New England Journal of Medicine, 2008
More effective and less resistance-prone antiviral agents are now available to treat hepatitis B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and reverse the progression of chronic HBV infection is important, given the evidence linking high-level HBV replication and the late consequences of chronic HBV infection ...
openaire +2 more sources
More effective and less resistance-prone antiviral agents are now available to treat hepatitis B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and reverse the progression of chronic HBV infection is important, given the evidence linking high-level HBV replication and the late consequences of chronic HBV infection ...
openaire +2 more sources
Hepatitis B virus in hepatocarcinogenesis
Journal of Cellular Physiology, 1999Hepatitis B virus (HBV) is an important etiologic agent of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Although the mechanism whereby HBV causes HCC is not fully understood, it is likely that there are many relevant molecular pathways that contribute to the development of HBV-associated HCC.
openaire +2 more sources
Hepatitis B Virus Morphogenesis
1996Hepatitis B viruses, or hepadnaviruses (hepatotropic DNA viruses), comprise a family of small enveloped DNA viruses that replicate through reverse transcription of an RNA intermediate; their replication cycle is hence a cyclic permutation of that of retroviruses which are RNA viruses replicating through a DNA intermediate.
openaire +2 more sources
The Hepatitis B Virus Receptor
Annual Review of Cell and Developmental Biology, 2015Hepatitis B virus (HBV) infection affects 240 million people worldwide. A liver-specific bile acid transporter named the sodium taurocholate cotransporting polypeptide (NTCP) has been identified as the cellular receptor for HBV and its satellite, the hepatitis D virus (HDV).
openaire +2 more sources
Current treatment and recent progress in gastric cancer
Ca-A Cancer Journal for Clinicians, 2021Smita S Joshi, Brian D Badgwell
exaly